Abstract: In general, the present disclosure is directed to systems and methods of evaluating a subject's risk of one or more complications associated with pelvic organ prolapse surgery. The method comprising: obtaining, by a computing system comprising one or more computing devices, sample data associated with the subject; inputting, by the computing system, the sample data into a machine-learned immune response model; receiving, by the computing system as an output of the machine-learned immune response model, one or more predictions of post-surgical complications of mesh exposure through the vaginal wall associated with the subject; and performing a pelvic organ prolapse repair surgery on the subject, wherein the surgery is performed based at least in part on the one or more predictions of post-surgical complications by the machine-learned immune response model associated with a likelihood of success.

Abstract: Disclosed herein are peptoids and methods for attenuating inflammatory responses, and more particularly RAGE-associated inflammatory responses.

Abstract: Devices (dot blot boxes) for use in immunoblotting are described. The dot blot boxes can include a series of hooks, clips or the like on opposite sides of a container for retaining a test strip there between. The dot blot boxes can be sized to retain a plurality of test strips generally parallel to one another such that they do not contact one another and do not contact the base of the container. A container can hold a fluid, e.g., a blocking buffer solution or antibody solution, and the test strips can be submerged in the fluid while retained in the container.

Abstract: The present disclosure has identified a unique cellular response to the pathogenic form of the amyloid-ß protein (Aß) and will employ a cell-based biosensor to leverage this response for early detection of Alzheimer's disease (AD) by determining if the pathogenic form of Aß is present in the cerebral spinal fluid or blood of a patient.

Abstract: Disclosed herein are peptoids and methods for attenuating inflammatory responses, and more particularly RAGE-associated inflammatory responses.

Abstract: Devices (dot blot boxes) for use in immunoblotting are described. The dot blot boxes can include a series of hooks, clips or the like on opposite sides of a container for retaining a test strip there between. The dot blot boxes can be sized to retain a plurality of test strips generally parallel to one another such that they do not contact one another and do not contact the base of the container. A container can hold a fluid, e.g., a blocking buffer solution or antibody solution, and the test strips can be submerged in the fluid while retained in the container.

Abstract: Provided herein are peptoids capable of inhibiting or reversing amyloid ? (A?) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least four monomers with a side-chain having an arylalkyl or aryl group. The peptoid may be achiral. Also provided are methods of using the peptoids to inhibit or reverse aggregation of A? and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.

Abstract: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.

Abstract: Provided herein are peptoids capable of inhibiting or reversing amyloid ? (A?) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least four monomers with a side-chain having an arylalkyl or aryl group. The peptoid may be achiral. Also provided are methods of using the peptoids to inhibit or reverse aggregation of A? and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.

Abstract: Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors and 15-PGDH activators described herein.

Abstract: Provided herein are peptoids capable of inhibiting or reversing amyloid ? (A?) fibril or plaque production. The peptoids form a helical structure with three monomers per helical turn and have at least two monomers with a side-chain having an arylalkyl group having the same chirality positioned such that the side-chains are on the same side of the peptoid. Also provided are methods of using the peptoids to inhibit or reverse aggregation of A? and methods of treating subjects with Alzheimer's disease (AD) or slowing the progression of AD.